Home LiteratureArticle Details
PMID: 22873125 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine.

Expert review of vaccines ·Vol. 11 ·No. 6 ·2012-06-00 ·Pages 663-76

Brumbaugh AR, Mobley HL

Abstract

Uncomplicated urinary tract infections (UTIs) are common, with nearly half of all women experiencing at least one UTI in their lifetime. This high frequency of infection results in huge annual economic costs, decreased workforce productivity and high patient morbidity. At least 80% of these infections are caused by uropathogenic Escherichia coli (UPEC). UPEC can reside side by side with commensal strains in the gastrointestinal tract and gain access to the bladder via colonization of the urethra. Antibiotics represent the current standard treatment for UTI; however, even after treatment, patients frequently suffer from recurrent infection with the same or different strains. In addition, successful long-term treatment has been complicated by a rise in both the number of antibiotic-resistant strains and the prevalence of antibiotic-resistance mechanisms. As a result, preventative approaches to UTI, such as vaccination, have been sought. This review summarizes recent advances in UPEC vaccine development and outlines future directions for the field.

MeSH Terms
Biomedical Research/trends Escherichia coli Infections/prevention & control Escherichia coli Vaccines/immunology Female Humans Urinary Tract Infections/prevention & control Uropathogenic Escherichia coli/immunology
Chemicals
Escherichia coli Vaccines
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Brumbaugh Ariel R
Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI, USA.
Mobley Harry L T
References (119)
119 references, click to expand
  1. Immunofluorescence study of fimbrial phase variation in Escherichia coli KS71.
    J Bacteriol. 1984 Nov;160(2):691-5 PMID: 6150023
  2. The innate immune response to uropathogenic Escherichia coli involves IL-17A in a murine model of urinary tract infection.
    J Immunol. 2010 Feb 15;184(4):2065-75 PMID: 20083670
  3. [Immunostimulatory activity of the vaccine used in the treatment of recurrent urinary infections. II].
    Bratisl Lek Listy. 1999 Apr;100(4):215-7 PMID: 10914146
  4. Molecular basis of uropathogenic Escherichia coli evasion of the innate immune response in the bladder.
    Infect Immun. 2008 Sep;76(9):3891-900 PMID: 18559433
  5. Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA).
    Int J Antimicrob Agents. 2005 Nov;26(5):380-8 PMID: 16243229
  6. Alpha-hemolysin contributes to the pathogenicity of piliated digalactoside-binding Escherichia coli in the kidney: efficacy of an alpha-hemolysin vaccine in preventing renal injury in the BALB/c mouse model of pyelonephritis.
    Infect Immun. 1991 Mar;59(3):1153-61 PMID: 1671776
  7. A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections.
    Eur Urol. 2005 Apr;47(4):542-8; discussion 548 PMID: 15774256
  8. Role of P-fimbrial-mediated adherence in pyelonephritis and persistence of uropathogenic Escherichia coli (UPEC) in the mammalian kidney.
    Kidney Int. 2007 Jul;72(1):19-25 PMID: 17396114
  9. An "omics" approach to uropathogenic Escherichia coli vaccinology.
    Trends Microbiol. 2009 Oct;17(10):431-2 PMID: 19758805
  10. Antibodies to Escherichia coli K and O antigens in protection against acute pyelonephritis.
    Prog Allergy. 1983;33:275-88 PMID: 6187016
  11. Co-trimoxazole and quinolone resistance in Escherichia coli isolated from urinary tract infections over the last 10 years.
    Int J Antimicrob Agents. 2005 Jul;26(1):75-7 PMID: 15955672
  12. Urologic diseases in America Project: analytical methods and principal findings.
    J Urol. 2005 Mar;173(3):933-7 PMID: 15711342
  13. Siderophore uptake in bacteria and the battle for iron with the host; a bird's eye view.
    Biometals. 2010 Aug;23(4):601-11 PMID: 20596754
  14. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections.
    Int J Antimicrob Agents. 2009 Nov;34(5):407-13 PMID: 19505803
  15. Phase I clinical trial of vaginal mucosal immunization for recurrent urinary tract infection.
    J Urol. 1994 Dec;152(6 Pt 2):2308-11 PMID: 7966729
  16. Oral immunotherapy in paraplegic patients with chronic urinary tract infections: a double-blind, placebo-controlled trial.
    J Urol. 1990 Apr;143(4):759-62; discussion 762-3 PMID: 2179584
  17. [Immunomodulation of recurrent urinary tract infections with Urvakol vaccine].
    Bratisl Lek Listy. 1999 May;100(5):246-51 PMID: 10500328
  18. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges.
    Vaccine. 2003 Jun 1;21 Suppl 2:S89-95 PMID: 12763689
  19. Vaginal immunization of monkeys against urinary tract infection with a multi-strain vaccine.
    J Urol. 1994 Jan;151(1):214-6 PMID: 8254817
  20. Host-pathogen interactions in urinary tract infection.
    Nat Rev Urol. 2010 Aug;7(8):430-41 PMID: 20647992
  21. The risks of symptomatic vaginal candidiasis after oral antibiotic therapy.
    Q J Med. 1993 Jul;86(7):419-24 PMID: 8210296
  22. TonB-dependent systems of uropathogenic Escherichia coli: aerobactin and heme transport and TonB are required for virulence in the mouse.
    Infect Immun. 2001 Oct;69(10):6179-85 PMID: 11553558
  23. Localization of a domain in the FimH adhesin of Escherichia coli type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection.
    J Clin Invest. 1997 Sep 1;100(5):1123-36 PMID: 9276729
  24. Role of type 1 fimbriae in the pathogenesis of ascending urinary tract infection induced by escherichia coli in mice.
    Infect Immun. 1983 Mar;39(3):1307-15 PMID: 6132876
  25. The O75X adhesin of uropathogenic Escherichia coli is a type IV collagen-binding protein.
    Mol Microbiol. 1989 Mar;3(3):329-37 PMID: 2568575
  26. Risk factors for second urinary tract infection among college women.
    Am J Epidemiol. 2000 Jun 15;151(12):1194-205 PMID: 10905532
  27. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli.
    J Infect Dis. 2000 Feb;181(2):774-8 PMID: 10669375
  28. Effects of the administration of cholera toxin as a mucosal adjuvant on the immune and protective response induced by Proteus mirabilis MrpA fimbrial protein in the urinary tract.
    Microbiol Immunol. 2009 Apr;53(4):233-40 PMID: 19714860
  29. Capsular polysaccharide and the O-specific antigen impede antibody binding: a potential obstacle for the successful development of an extraintestinal pathogenic Escherichia coli vaccine.
    Vaccine. 2009 Jan 14;27(3):388-95 PMID: 19014988
  30. Phase variation of type 1 fimbriae in Escherichia coli is under transcriptional control.
    Science. 1981 Oct 16;214(4518):337-9 PMID: 6116279
  31. Prevention of colonization of the urinary tract of mice with Escherichia coli by blocking of bacterial adherence with methyl alpha-D-mannopyranoside.
    J Infect Dis. 1979 Mar;139(3):329-32 PMID: 376757
  32. Origins and virulence mechanisms of uropathogenic Escherichia coli.
    Exp Mol Pathol. 2008 Aug;85(1):11-9 PMID: 18482721
  33. Aerobactin-mediated iron uptake by Escherichia coli isolates from human extraintestinal infections.
    Infect Immun. 1986 Mar;51(3):966-8 PMID: 3512445
  34. Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding.
    J Cell Sci. 2001 Nov;114(Pt 22):4095-103 PMID: 11739641
  35. Prevention of recurrent urinary tract infections with immuno-active E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies.
    Int J Antimicrob Agents. 2002 Jun;19(6):451-6 PMID: 12135831
  36. Fimch antiserum inhibits the adherence of Escherichia coli to cells collected by voided urine specimens of diabetic women.
    J Urol. 2004 Apr;171(4):1589-93 PMID: 15017227
  37. Extended virulence genotypes and phylogenetic background of Escherichia coli isolates from patients with cystitis, pyelonephritis, or prostatitis.
    J Infect Dis. 2005 Jan 1;191(1):46-50 PMID: 15593002
  38. Vaccination utilizing the FimCH complex as a strategy to prevent Escherichia coli urinary tract infections.
    J Infect Dis. 2001 Mar 1;183 Suppl 1:S84-6 PMID: 11171023
  39. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing.
    PLoS Biol. 2008 Nov 18;6(11):e280 PMID: 19018661
  40. Escherichia coli global gene expression in urine from women with urinary tract infection.
    PLoS Pathog. 2010 Nov 11;6(11):e1001187 PMID: 21085611
  41. Vaginal mucosal immunization for recurrent urinary tract infection: phase II clinical trial.
    J Urol. 1997 Jun;157(6):2049-52 PMID: 9146577
  42. Cellular and humoral systemic and mucosal immune responses stimulated by an oral polybacterial immunomodulator in patients with chronic urinary tract infections.
    Int J Immunopathol Pharmacol. 2005 Jul-Sep;18(3):457-473 PMID: 16164822
  43. Treatment of bacterial infections of the female urinary tract by immunization of the patients.
    Urol Int. 1987;42(5):338-41 PMID: 3324441
  44. Antibiotic resistance and pyelonephritis.
    Clin Infect Dis. 2007 Aug 1;45(3):281-3 PMID: 17599304
  45. Cytotoxic necrotizing factor type 1-positive Escherichia coli causes increased inflammation and tissue damage to the prostate in a rat prostatitis model.
    Infect Immun. 2001 Oct;69(10):6515-9 PMID: 11553597
  46. Mast cell activators: a new class of highly effective vaccine adjuvants.
    Nat Med. 2008 May;14(5):536-41 PMID: 18425129
  47. Protective capacity of antibodies against Escherichia coli and K antigens.
    Infect Immun. 1977 Aug;17(2):286-9 PMID: 70410
  48. Recurrent urinary tract infections in women: diagnosis and management.
    Am Fam Physician. 2010 Sep 15;82(6):638-43 PMID: 20842992
  49. In vivo phase variation of Escherichia coli type 1 fimbrial genes in women with urinary tract infection.
    Infect Immun. 1998 Jul;66(7):3303-10 PMID: 9632599
  50. Virulence factors in Escherichia coli urinary tract infection.
    Clin Microbiol Rev. 1991 Jan;4(1):80-128 PMID: 1672263
  51. Role of the K2 capsule in Escherichia coli urinary tract infection and serum resistance.
    J Infect Dis. 2009 Jun 1;199(11):1689-97 PMID: 19432551
  52. Enhancement of the bladder defense mechanism by immunization.
    Invest Urol. 1969 Mar;6(5):520-6 PMID: 4887493
  53. Quantitative metabolomics reveals an epigenetic blueprint for iron acquisition in uropathogenic Escherichia coli.
    PLoS Pathog. 2009 Feb;5(2):e1000305 PMID: 19229321
  54. Development of experimental model of chronic pyelonephritis with Escherichia coli O75:K5:H-bearing Dr fimbriae: mutation in the dra region prevented tubulointerstitial nephritis.
    J Clin Invest. 1997 Apr 1;99(7):1662-72 PMID: 9120010
  55. Hemolysin of uropathogenic Escherichia coli evokes extensive shedding of the uroepithelium and hemorrhage in bladder tissue within the first 24 hours after intraurethral inoculation of mice.
    Infect Immun. 2008 Jul;76(7):2978-90 PMID: 18443089
  56. Biosynthesis and assembly of capsular polysaccharides in Escherichia coli.
    Annu Rev Biochem. 2006;75:39-68 PMID: 16756484
  57. A live-attenuated vaccine for the treatment of urinary tract infection by uropathogenic Escherichia coli.
    J Infect Dis. 2009 Jul 15;200(2):263-72 PMID: 19522648
  58. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.
    Clin Infect Dis. 2011 Mar 1;52(5):e103-20 PMID: 21292654
  59. Vaginal mucosal immunization for recurrent urinary tract infection: extended phase II clinical trial.
    J Infect Dis. 2001 Mar 1;183 Suppl 1:S81-3 PMID: 11171022
  60. First multi-epitope subunit vaccine against extraintestinal pathogenic Escherichia coli delivered by a bacterial type-3 secretion system (T3SS).
    Int J Med Microbiol. 2012 Jan;302(1):10-8 PMID: 22000741
  61. Antibiotherapy and pathogenesis of uncomplicated UTI: difficult relationships.
    J Appl Microbiol. 2009 Jun;106(6):1779-91 PMID: 19210569
  62. Delivery of foreign antigens by engineered outer membrane vesicle vaccines.
    Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3099-104 PMID: 20133740
  63. Structure, assembly and regulation of expression of capsules in Escherichia coli.
    Mol Microbiol. 1999 Mar;31(5):1307-19 PMID: 10200953
  64. Antibody responses and protection from pyelonephritis following vaccination with purified Escherichia coli PapDG protein.
    J Urol. 2004 Apr;171(4):1682-5 PMID: 15017266
  65. Urinary antibody response after immunisation with a vaccine against urinary tract infection.
    Urol Res. 1989;17(6):361-6 PMID: 2623792
  66. Molecular epidemiology of Escherichia coli mediated urinary tract infections.
    Front Biosci. 2003 Jan 01;8:e235-44 PMID: 12456300
  67. Chemical characterization of a neural cell adhesion molecule purified from embryonic brain membranes.
    J Biol Chem. 1982 Jul 10;257(13):7720-9 PMID: 7085646
  68. Diagnosis and management of uncomplicated urinary tract infections.
    Am Fam Physician. 2005 Aug 1;72(3):451-6 PMID: 16100859
  69. Antigen-specific responses accelerate bacterial clearance in the bladder.
    J Immunol. 2006 Mar 1;176(5):3080-6 PMID: 16493067
  70. Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study.
    Antimicrob Agents Chemother. 2006 Jun;50(6):2251-4 PMID: 16723598
  71. A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate.
    Vaccine. 2007 May 10;25(19):3859-70 PMID: 17306426
  72. 2006 National Hospital Discharge Survey.
    Natl Health Stat Report. 2008 Jul 30;(5):1-20 PMID: 18841653
  73. Redundancy and specificity of Escherichia coli iron acquisition systems during urinary tract infection.
    Infect Immun. 2011 Mar;79(3):1225-35 PMID: 21220482
  74. Acquisition of siderophores in gram-negative bacteria.
    Nat Rev Mol Cell Biol. 2003 Feb;4(2):105-16 PMID: 12563288
  75. The structure of the capsular polysaccharide (K5 antigen) of urinary-tract-infective Escherichia coli 010:K5:H4. A polymer similar to desulfo-heparin.
    Eur J Biochem. 1981 May 15;116(2):359-64 PMID: 7018909
  76. Prevention of pyelonephritis by immunization with P-fimbriae.
    J Urol. 1984 Mar;131(3):602-7 PMID: 6199527
  77. Sticky fibers and uropathogenesis: bacterial adhesins in the urinary tract.
    Future Microbiol. 2006 Jun;1(1):75-87 PMID: 17661687
  78. Transcriptome of uropathogenic Escherichia coli during urinary tract infection.
    Infect Immun. 2004 Nov;72(11):6373-81 PMID: 15501767
  79. Type 1 fimbrial adhesin FimH elicits an immune response that enhances cell adhesion of Escherichia coli.
    Infect Immun. 2011 Oct;79(10):3895-904 PMID: 21768279
  80. Recurring urinary tract infection: incidence and risk factors.
    Am J Public Health. 1990 Mar;80(3):331-3 PMID: 2305919
  81. Contribution of siderophore systems to growth and urinary tract colonization of asymptomatic bacteriuria Escherichia coli.
    Infect Immun. 2012 Jan;80(1):333-44 PMID: 21930757
  82. Waging war against uropathogenic Escherichia coli: winning back the urinary tract.
    Infect Immun. 2010 Feb;78(2):568-85 PMID: 19917708
  83. Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract.
    Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9827-32 PMID: 8790416
  84. Risk factors for development of multiple-class resistance to Streptococcus pneumoniae Strains in Belgium over a 10-year period: antimicrobial consumption, population density, and geographic location.
    Antimicrob Agents Chemother. 2007 Oct;51(10):3491-7 PMID: 17682102
  85. The epidemiology of urinary tract infection.
    Nat Rev Urol. 2010 Dec;7(12):653-60 PMID: 21139641
  86. Mutational analysis of receptor binding mediated by the Dr family of Escherichia coli adhesins.
    Mol Microbiol. 1997 Jan;23(2):365-79 PMID: 9044270
  87. Protection by a polyvalent vaccine against challenge infection and pyelonephritis.
    Urol Res. 1992;20(2):177-81 PMID: 1553795
  88. Vaxign: the first web-based vaccine design program for reverse vaccinology and applications for vaccine development.
    J Biomed Biotechnol. 2010;2010:297505 PMID: 20671958
  89. Protection against acute, ascending pyelonephritis caused by Escherichia coli in rats, using isolated capsular antigen conjugated to bovine serum albumin.
    Infect Immun. 1983 Jan;39(1):142-6 PMID: 6337094
  90. Intracellular bacterial biofilm-like pods in urinary tract infections.
    Science. 2003 Jul 4;301(5629):105-7 PMID: 12843396
  91. Subversion of Toll-like receptor signaling by a unique family of bacterial Toll/interleukin-1 receptor domain-containing proteins.
    Nat Med. 2008 Apr;14(4):399-406 PMID: 18327267
  92. The common mucosal immune system and current strategies for induction of immune responses in external secretions.
    J Clin Immunol. 1987 Jul;7(4):265-76 PMID: 3301884
  93. Mucosal immunization with iron receptor antigens protects against urinary tract infection.
    PLoS Pathog. 2009 Sep;5(9):e1000586 PMID: 19806177
  94. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections.
    Ann Intern Med. 2001 Jul 3;135(1):41-50 PMID: 11434731
  95. Vaccination with purified Dr Fimbriae reduces mortality associated with chronic urinary tract infection due to Escherichia coli bearing Dr adhesin.
    Infect Immun. 2005 Jan;73(1):627-31 PMID: 15618205
  96. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease.
    Ann Intern Med. 2006 Nov 21;145(10):758-64 PMID: 17116920
  97. Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli.
    Proc Natl Acad Sci U S A. 2010 May 18;107(20):9072-7 PMID: 20439758
  98. Uropathogenic Escherichia coli as agents of diverse non-urinary tract extraintestinal infections.
    J Infect Dis. 2002 Sep 15;186(6):859-64 PMID: 12198625
  99. Pyelonephritic Escherichia coli expressing P fimbriae decrease immune response of the mouse kidney.
    J Am Soc Nephrol. 2005 Dec;16(12):3583-91 PMID: 16236807
  100. A prospective multi-center trial of Escherichia coli extract for the prophylactic treatment of patients with chronically recurrent cystitis.
    J Korean Med Sci. 2010 Mar;25(3):435-9 PMID: 20191044
  101. Polysaccharide antigens of Escherichia coli.
    Rev Infect Dis. 1987 Sep-Oct;9 Suppl 5:S517-26 PMID: 2446369
  102. A multiepitope subunit vaccine conveys protection against extraintestinal pathogenic Escherichia coli in mice.
    Infect Immun. 2010 Aug;78(8):3432-42 PMID: 20498257
  103. Emerging bacterial pathogens. Preface.
    Contrib Microbiol. 2001;8:XI-XIV PMID: 11764741
  104. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination.
    Science. 1997 Apr 25;276(5312):607-11 PMID: 9110982
  105. Protective efficacy and immunogenicity of Escherichia coli K13 diphtheria toxoid conjugate against experimental ascending pyelonephritis.
    Med Microbiol Immunol. 2005 Aug;194(4):211-7 PMID: 15909203
  106. Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections.
    J Urol. 2003 Sep;170(3):867-9 PMID: 12913718
  107. Immunization against urinary tract infection with a multi-valent vaginal vaccine.
    J Urol. 1991 Jul;146(1):223-6 PMID: 2056594
  108. Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial.
    J Urol. 2007 Apr;177(4):1349-53; quiz 1591 PMID: 17382730
  109. Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli.
    Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):17020-4 PMID: 12471157
  110. Targeted vaccine adjuvants based on modified cholera toxin.
    Curr Mol Med. 2005 Sep;5(6):591-7 PMID: 16178769
  111. Oral immunotherapy of recurrent urinary tract infections: a double-blind placebo-controlled multicenter study.
    J Urol. 1993 Sep;150(3):917-21 PMID: 8345609
  112. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Vaccine. 2006 Jul 7;24(27-28):5627-36 PMID: 16740348
  113. Identification of candidates for a subunit vaccine against extraintestinal pathogenic Escherichia coli.
    Infect Immun. 2007 Apr;75(4):1916-25 PMID: 17145948
  114. Fimbrial profiles predict virulence of uropathogenic Escherichia coli strains: contribution of ygi and yad fimbriae.
    Infect Immun. 2011 Dec;79(12):4753-63 PMID: 21911462
  115. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs.
    Infect Dis Clin North Am. 2003 Jun;17(2):227-41 PMID: 12848468
  116. The Siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate.
    Infect Immun. 2003 Dec;71(12):7164-9 PMID: 14638809
  117. A murine model of urinary tract infection.
    Nat Protoc. 2009;4(8):1230-43 PMID: 19644462
  118. Molecular basis of Escherichia coli colonization of the upper urinary tract in BALB/c mice. Gal-Gal pili immunization prevents Escherichia coli pyelonephritis in the BALB/c mouse model of human pyelonephritis.
    J Clin Invest. 1985 Feb;75(2):347-60 PMID: 2857730
  119. Treatment of recurrent urinary tract infections: efficacy of an orally administered biological response modifier.
    Urol Int. 1986;41(6):444-6 PMID: 3547993
Article Info
Journal
Expert review of vaccines
Abbr.
Expert Rev Vaccines
ISSN
1744-8395
DOI
10.1586/erv.12.36
Published
2012-06-00
Pages
663-76
Language
English
Region
England
NLM ID
101155475
PMCID
PMC3498450
Subset
IM
Grants
NIDDK NIH HHS · R01 DK094777 · United States
NIAID NIH HHS · AI43365 · United States
NIAID NIH HHS · AI059722 · United States
NIAID NIH HHS · R56 AI091751 · United States
NIAID NIH HHS · R01 AI059722 · United States
External Links
PubMed source DOI: 10.1586/erv.12.36 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2